[
  {
    "statement": "Antibiotic.",
    "reference_no": "None",
    "reference": "No citation identified in the source text.",
    "matched_paper": "None",
    "matched_evidence": "The system could not identify a superscript or citation number for this specific statement in the PDF.",
    "validation_result": "Refuted",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "",
    "analysis_summary": "This statement was extracted but has no linked reference number to validate against.",
    "confidence_band": "LOW"
  },
  {
    "statement": "amikacin. 3.5-5.5. Local site pain. Redness at injection site.",
    "reference_no": "1,2,3",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 2.Amikacin Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Injection site pain\n- 3.Amikin (Amikacin)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: Side effects of Amikin (amikacin) include: | • injection site reactions (pain, irritation, redness).",
    "validation_result": "Supported",
    "page_location": "Page 6, under the 'Local' section | Page 1, under \"What Are Side Effects of Amikin?\"",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ampicillin. 8.0-10.0. Thrombo-phlebitis. Local site pain. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "4,5,6,7",
    "reference": "",
    "matched_paper": "Multiple PDFs (3/4 support)",
    "matched_evidence": "- 4.Ampicillin injections SPC.pdf: Ampicillin solutions should always be administered separately, unless compatibility with other infusion solutions or medicines has been established.|This medicinal product must not be mixed with other solutions except those mentioned in section 6.6.\n- 5.Ampicillin - StatPearls - NCBI Bookshelf.pdf: Local Adverse Reactions | • Pain at IM/IV injection site | • Thrombophlebitis\n- 6.Ampicillin_ Package Insert _ Prescribing Information.pdf: The pH range of the reconstituted solution is 8 to 10.",
    "validation_result": "Supported",
    "page_location": "Section 6.2 Incompatibilities, page 5 | Page 5, under the section \"Adverse Effects\", subsection \"Local Adverse Reactions\" | Page 2, under Ampicillin - Clinical Pharmacology",
    "confidence_score": 0.8666666666666667,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 4 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ampicillin and sulbactam. 8.0-10.0. Thrombo-phlebitis. Local site pain. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "8,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 8.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: The pH of the solutions is between 8 and 10.|Pain at IV injection site - 3%|Thrombophlebitis - 3%\n- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: The pH of the solutions is between 8 and 10.|Pain at IV injection site - 3%|Thrombophlebitis - 3%",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 10 | Page 2, Page 10",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "azithromycin. NR*. Potential for damage from extravasation. Local site pain. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Pain at IV injection site - 3%|General Disorders and Administration Site Conditions: Injection site reaction.",
    "validation_result": "Supported",
    "page_location": "Page 10, Page 11",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam. 4.5-7.5. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,10",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 10.Aztreonam_ Package Insert _ Prescribing Information.pdf: Aqueous solutions of the product have a pH in the range of 4.5 to 7.5.|Local reactions such as phlebitis/thrombophlebitis following intravenous administration, and discomfort/swelling at the injection site following intramuscular administration occurred at rates of approximately 1.9% and 2.4%, respectively.|In 343 pediatric patients receiving intravenous therapy, the following local reactions were noted: pain (12%), erythema (2.9%), induration (0.9%), and phlebitis (2.1%).|With any intermittent infusion of aztreonam and another drug with which it is not pharmaceutically compatible, the common delivery tube should be flushed before and after delivery of aztreonam with any appropriate infusion solution compatible with both drug solutions; the drugs should not be delivered simultaneously.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 12, Page 13, Page 17",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam and avibactam sodium. 4.5-7.5. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "11",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 11.Collins SR, Azithromycin.pdf: AZTREONAM\n(az-TREE-oh-nam)\nAzactam\nAntibacterial (monobactam)\npH 4.5 to 7.5",
    "validation_result": "Supported",
    "page_location": "Page 6, near the bottom",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "capreomycin. 4.0-8.0. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "12,13",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 12.Capreomycin.pdf: Human adverse reactions: Pain and excessive bleeding at the injection site have been reported, sterile abscesses have been noted, and rare cases of thrombocytopenia [DrugBank].\n- 13.Capreomycin_ Package Insert _ Prescribing Information.pdf: Pain and induration at the injection site have been observed.",
    "validation_result": "Supported",
    "page_location": "Page 2, under Human adverse reactions | Page 6, Adverse Reactions/Side Effects",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefazolin. 4.5-7.0. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,14",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 14.Cefazolin Injection_ Package Insert _ Prescribing Info.pdf: Rare instances of phlebitis have been reported at site of injection.|Pain at the site of injection after intramuscular administration has occurred infrequently.",
    "validation_result": "Supported",
    "page_location": "Page 8, under Adverse Reactions/Side Effects, Local Reactions",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefepime. 4.0-6.0. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,15",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 15.Cefepime_ Package Insert _ Prescribing Information.pdf: Local adverse reactions (3%), including phlebitis (1.3%), pain and/or inflammation (0.6%)*; rash (1.1%)",
    "validation_result": "Supported",
    "page_location": "Page 13, Table 5: Adverse Reactions in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefiderocol sulfate tosylate. 5.2-5.8. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,16,17",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 16.Fetroja (Cefiderocol for Injection)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: The pH of the reconstituted solution of 1gram cefiderocol (1 vial) dissolved in 10 mL water is 5.2 to 5.8.|Infusion site reactions include infusion site erythema, inflammation, pain, pruritis, injection site pain, and phlebitis.\n- 17.Fetroja_ Package Insert _ Prescribing Information.pdf: Table 4 Selected Adverse Reactions Occurring in ≥ 2% of cUTI Patients Receiving FETROJA in Trial 1\nInfusion site reactions include infusion site erythema, inflammation, pain, pruritis, injection site pain, and phlebitis.",
    "validation_result": "Supported",
    "page_location": "Page 4, Page 8 | Page 10, Table 4",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefotaxime sodium. 5.0-7.5. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,18,19",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 18.Cefotaxime_ Package Insert _ Prescribing Information.pdf: Solutions of Cefotaxime for Injection, USP range from very pale yellow to light amber depending on the concentration and the diluent used. | The pH of the injectable solutions usually ranges from 5.0 to 7.5.|General disorders and administration site conditions - Inflammatory reactions at the injection site, including phlebitis/thrombophlebitis.|Cefotaxime, like other parenteral anti-infective drugs, may be locally irritating to tissues. In most cases, perivascular extravasation of cefotaxime responds to changing of the infusion site. In rare instances, extensive perivascular extravasation of cefotaxime may result in tissue damage and require surgical treatment. To minimize the potential for tissue inflammation, infusion sites should be monitored regularly and changed when appropriate.|NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.\n- 19.Cefotaxime_ Package Insert _ Prescribing Information.pdf: Solutions of Cefotaxime for Injection, USP range from very pale yellow to light amber depending on the concentration and the diluent used. | The pH of the injectable solutions usually ranges from 5.0 to 7.5.|General disorders and administration site conditions - Inflammatory reactions at the injection site, including phlebitis/thrombophlebitis.|Cefotaxime, like other parenteral anti-infective drugs, may be locally irritating to tissues. In most cases, perivascular extravasation of cefotaxime responds to changing of the infusion site. In rare instances, extensive perivascular extravasation of cefotaxime may result in tissue damage and require surgical treatment. To minimize the potential for tissue inflammation, infusion sites should be monitored regularly and changed when appropriate.|NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 11, Page 8, Page 14 | Page 1, Page 11, Page 8, Page 14",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefotetan disodium. 4.5-6.5. Phlebitis. Thrombo-phlebitis. Local site pain. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,20",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 20.Cefotan_ Package Insert _ Prescribing Information.pdf: The pH of freshly reconstituted solutions is usually between 4.5 to 6.5.|Local: effects were reported in less than 1% of patients and included phlebitis at the site of injection (1 in 300), and discomfort (1 in 500).|NOTE: Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. If CEFOTAN® and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 12, Page 16",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoxitin. 4.2-7.0. Phlebitis. Thrombo-phlebitis. Local site pain. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,21",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 21.Cefoxitin Package Insert Prescribing Information.pdf: The pH of freshly constituted solutions usually ranges from 4.2 to 7.0.|Thrombophlebitis has occurred with intravenous administration.|RECONSTITUTED BULK SOLUTION SHOULD NOT BE USED FOR DIRECT INFUSION.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 9, Page 13",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoperazone. 4.5-6.5. Phlebitis. Local site pain.",
    "reference_no": "1,22,23",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 22.Cefobide.pdf: The pH of a 25% (w/v) freshly reconstituted solution varies between 4.5–6.5 and the solution ranges from colorless to straw yellow depending on the concentration.|Local Reactions: CEFOBID is well tolerated following intramuscular administration.|Occasionally, transient pain (1 in 140) may follow administration by this route.|When CEFOBID is administered by intravenous infusion some patients may develop phlebitis (1 in 120) at the infusion site.\n- 23.Cefoperazone Side Effects_ Common, Severe, Long Term.pdf: Local side effects have included pain after intramuscular injection and phlebitis after intravenous infusion.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 12 | Page 2, under the 'Local' section",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftaroline fosamil. 4.8-6.5. Phlebitis. Local site pain.",
    "reference_no": "1,24",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 24.Teflaro Package Insert  Prescribing Information.pdf: The pH of the constituted solution is pH 4.8 to 6.5.|Phlebitis",
    "validation_result": "Supported",
    "page_location": "Page 16, Page 10",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftazidime. 5.0-8.0. Phlebitis. Local site pain. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,25",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 25.Ceftazidime Package Insert  Prescribing Information.pdf: Solutions of ceftazidime for injection, USP range in color from light yellow to amber, depending on the diluent and volume used. | The pH of freshly constituted solutions usually ranges from 5 to 8.|Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection (1 in 69 patients).|General\nAnaphylaxis; allergic reactions, which, in rare instances, were severe (e.g., cardiopulmonary arrest); urticaria;\npain at injection site.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 10",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "amikacin. Additional Consideration. Do not physically premix with other drugs; administer separately as recommended by manufacturer. Inactivated in solution with beta-lactam antibiotics (e.g., cephalosporins, penicillins) and vancomycin. Do not mix in the same solution. Appropriate spacing required because of physical incompatibilities.¹",
    "reference_no": "1,2,3",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 3.Amikin (Amikacin)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: Amikacin should not be physically premixed with other drugs but should be administered separately according to the recommended dosage and route.|In vitro mixing of aminoglycosides with beta-lactam antibiotics (penicillin or cephalosporin) may result in a significant mutual inactivation.",
    "validation_result": "Supported",
    "page_location": "Page 5, Page 8",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ampicillin 4,5,6,7. Additional Consideration. Ampicillin solutions should always be administered separately, unless compatibility with other infusion solutions or medicines has been established. Ampicillin solutions should not be mixed with aminoglycosides, metronidazole and injectable tetracycline derivatives such as oxytetracycline, rolitetracycline and doxycycline. Visual signs of incompatibility are precipitation, clouding and discoloration.6",
    "reference_no": "4,5,6,7",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/4 support)",
    "matched_evidence": "- 4.Ampicillin injections SPC.pdf: Ampicillin solutions should always be administered separately, unless compatibility with other infusion solutions or medicines has been established.|Ampicillin solutions should not be mixed with aminoglycosides, metronidazole and injectable tetracycline derivatives such as oxytetracycline, rolitetracycline and doxycycline.|Visual signs of incompatibility are precipitation, clouding and discoloration.",
    "validation_result": "Supported",
    "page_location": "Page 5, Section 6.2 Incompatibilities",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 4 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ampicillin and sulbactam 8,9. Additional Consideration. Frequently used concomitantly with aminoglycosides (e.g., gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer at separate sites.¹",
    "reference_no": "8,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 8.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Ampicillin and sulbactam for injection and aminoglycosides should be reconstituted and administered separately, due to the in vitro inactivation of aminoglycosides by any of the aminopenicillins.\n- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Ampicillin and sulbactam for injection and aminoglycosides should be reconstituted and administered separately, due to the in vitro inactivation of aminoglycosides by any of the aminopenicillins.",
    "validation_result": "Supported",
    "page_location": "Page 14, Compatibility, Reconstitution and Stability | Page 14, under COMPATIBILITY, RECONSTITUTION AND STABILITY",
    "confidence_score": 0.975,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "azithromycin 1,9. Additional Consideration. Manufacturer states, \"Other IV substances, additives, or medications should not be added to azithromycin, or infused simultaneously through the same IV line.\" Flush IV line with a compatible IV fluid before and after administration. ¹ Local IV site reactions have been reported with the intravenous administration of azithromycin. All volunteers who received infusate concentrations above 2.0 mg/mL experienced local IV site reactions and, therefore, higher concentrations should be avoided. 9",
    "reference_no": "1,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Pain at IV injection site - 3%",
    "validation_result": "Supported",
    "page_location": "Page 10, under Adverse Reactions/Side Effects, Local Adverse Reactions",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam 1,10. Additional Consideration. Do not infuse simultaneously with other drugs or solutions except in proven compatibility.¹",
    "reference_no": "1,10",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 10.Aztreonam_ Package Insert _ Prescribing Information.pdf: With any intermittent infusion of aztreonam and another drug with which it is not pharmaceutically compatible, the common delivery tube should be flushed before and after delivery of aztreonam with any appropriate infusion solution compatible with both drug solutions; the drugs should not be delivered simultaneously.",
    "validation_result": "Supported",
    "page_location": "Page 17, Intravenous Administration, Infusion",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam and avibactam sodium11. Additional Consideration. Emblaveo is administered by intravenous infusion over 3 hours. This medicinal product must not be mixed with other medicinal products except sodium chloride (0.9%) solution for injection, glucose (5%) solution for injection, or Lactated Ringer's solution as mentioned below.11",
    "reference_no": "11",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 11.Collins SR, Azithromycin.pdf: I am sorry, but I could not find any information about aztreonam and avibactam sodium, Emblaveo, or the specific infusion details mentioned in the statement within the provided document. The document primarily discusses azithromycin.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "capreomycin 12,13. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush IV line before and after administration.¹",
    "reference_no": "12,13",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 12.Capreomycin.pdf: The aminoglycosides and CAP cannot be adminis-tered orally.",
    "validation_result": "Supported",
    "page_location": "Page 2, Efficacy in humans",
    "confidence_score": 0.6,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "cefazolin 1,14. Additional Consideration. Temporarily discontinuing other solutions infusing at the same site during intermittent infusion. May be used concomitantly with aminoglycosides (e.g., gentamicin, tobramycin), aminophylline, metronidazole, and vancomycin, but these drugs must never be mixed in the same infusion (mutual inactivation or other potential interactions). If concurrent therapy with cefepime is indicated, each of these antibiotics can be administered separately.¹",
    "reference_no": "1,14",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 14.Cefazolin Injection_ Package Insert _ Prescribing Info.pdf: None",
    "validation_result": "Not Found",
    "page_location": "",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "cefepime 1,15. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,15",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 15.Cefepime_ Package Insert _ Prescribing Information.pdf: Do not add solutions of cefepime for injection, to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction. However, if concurrent therapy with cefepime for injection is indicated, each of these antibiotics can be administered separately.",
    "validation_result": "Supported",
    "page_location": "Page 10, Drug Interactions",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefiderocol sulfate tosylate 1,16,17. Additional Consideration. Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. If Cefotan and aminoglycosides are to administered to the same patient, they must be administered separately and not as a mixed injection.20",
    "reference_no": "1,16,17",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 16.Fetroja (Cefiderocol for Injection)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: None\n- 17.Fetroja_ Package Insert _ Prescribing Information.pdf: None",
    "validation_result": "Not Found",
    "page_location": "",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "cefotaxime sodium 1,18,19. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,18,19",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 18.Cefotaxime_ Package Insert _ Prescribing Information.pdf: NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.\n- 19.Cefotaxime_ Package Insert _ Prescribing Information.pdf: NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 14, Preparation of cefotaxime for injection sterile | Page 14, Preparation of cefotaxime for injection sterile",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefotetan disodium 1,20. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,20",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 20.Cefotan_ Package Insert _ Prescribing Information.pdf: NOTE: Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. |If CEFOTAN® and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 16, Intravenous Administration section",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoxitin 1,21. Additional Consideration. Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them. 22",
    "reference_no": "1,21",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 21.Cefoxitin Package Insert Prescribing Information.pdf: Solutions of Cefoxitin for Injection, USP range from colorless to light amber in color.|The pH of freshly constituted solutions usually ranges from 4.2 to 7.0.|Solutions of Cefoxitin for Injection, like those of most beta-lactam antibiotics, should not be added to aminoglycoside solutions (e.g., gentamicin sulfate, tobramycin sulfate, amikacin sulfate) because of potential interaction.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 14",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoperazone 1,22,23. Additional Consideration. Manufacturer states, Should not be mixed with or physically added to solutions containing other drugs.¹",
    "reference_no": "1,22,23",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 22.Cefobide.pdf: Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them.",
    "validation_result": "Supported",
    "page_location": "Page 13, Dosage and Administration section",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftaroline fosamil 1,24. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin, and tobramycin), but these drugs must never be mixed in the same infusion (mutual inactivation). May exhibit a physical incompatibility with vancomycin depending on concentration. If aminoglycosides or vancomycin are given concurrently, administer separately and flush IV line before and after administration. Manufacturer recommends temporarily discontinuing other solutions infusing at the same site during intermittent infusion and states, \"Do not add supplementary medications to premixed plastic IV containers.¹",
    "reference_no": "1,24",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 24.Teflaro Package Insert  Prescribing Information.pdf: The compatibility of Teflaro with other drugs has not been established. Teflaro should not be mixed with or physically added to solutions containing other drugs.",
    "validation_result": "Supported",
    "page_location": "Page 7, section 2.6 Drug Compatibilities",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftazidime 1,25. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,25",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 25.Ceftazidime Package Insert  Prescribing Information.pdf: Solutions of ceftazidime for injection, like those of most beta-lactam antibacterial drugs, should not be added to solutions of aminoglycoside antibacterial drugs because of potential interaction.|However, if concurrent therapy with ceftazidime for injection and an aminoglycoside is indicated, each of these antibacterial drugs can be administered separately to the same patient.",
    "validation_result": "Supported",
    "page_location": "Page 14, Compatibility and Stability section",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftizoxime. Phlebitis. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "26,27",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 26.Ceftizoxime Uses, Side Effects & Warnings.pdf: • severe pain, burning, irritation, or skin changes where the needle was placed;|• pain, irritation, or hardening where the injection was given;\n- 27.Ceftizoxime Side Effects_ Common, Severe, Long Term.pdf: Local side effects have included burning, cellulitis, phlebitis, pain, induration, tenderness, and paresthesia at the injection site in 1% to 5% of patients.",
    "validation_result": "Supported",
    "page_location": "Page 3 and 4, under Ceftizoxime injection side effects | Page 3, under the 'Local' section",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftobiprole medocaril\nsodium. 4.5-5.5. Thrombosis of vessel. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,28,29",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 28.Ceftobiprole Medocaril Side Effects_ Common, Severe, Long Term.pdf: Applies to ceftobiprole medocaril: intravenous powder for injection.|• Frequency not reported: Thrombosis\n- 29.ZEVTERA (ceftobiprole medocaril) Highlights of Prescribing Information. U.S. Food and Drug Administration..pdf: The pH of the reconstituted solution is 4.5–5.5.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 2 | Page 21, under section 11 DESCRIPTION",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftolozane/tazobactam. 5.0-7.0. Phlebitis. Thrombosis of vessel. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,30",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 30.Zerbaxa.pdf: The pH of an aqueous solution of the drug substance is 5.0-7.0.|Table 7: Adverse Reactions Occurring in 4% or Greater of Paediatric Patients (birth to less than 18 years of age) Receiving ZERBAXA (ceftolozane/tazobactam) in either the cIAI or cUTI Clinical Trial...Phlebitis5 4 (6) 0 (0) 1 (1) 1 (3)|ZERBAXA (ceftolozane/tazobactam) should not be infused simultaneously with other medications via the same intravenous line.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 13, Page 2",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftriaxone. 6.6-6.7. Phlebitis. Thrombo-phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,31",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 31..Ceftriaxone Package Insert  Prescribing Information.pdf: Ceftriaxone sodium is a white to yellowish crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7.|Pain, induration and tenderness was 1% overall. Phlebitis was reported in <1% after IV administration.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 13",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefuroxime. 5.0-8.5. Thrombo-phlebitis. Local site pain on Infusion. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,32",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 32.Cefuroxime Injection Package Insert  Prescribing Info.pdf: The pH of freshly constituted solutions usually ranges from 6 to 8.5.|Thrombophlebitis has occurred with IV administration in 1 in 60 patients.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 8",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "chloramphenicol\nsodium succinate. 6.4-7.0. Thrombo-phlebitis. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,33",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 33.Chloramphenicol_ Indications, Side Effects, Warnings - Drugs.com.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "Throughout the document",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "ciprofloxacin. 3.5-4.6. Thrombo-phlebitis. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,34",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 34.Ciprofloxacin Injection Package Insert  Prescribing.pdf: The pH range for the 0.2% ready-for-use infusion solutions is 3.5 to 4.6.|The following adverse reactions have been reported from worldwide marketing experience with fluoroquinolones, including ciprofloxacin.|Thrombophlebitis|Ciprofloxacin injection should be administered by intravenous infusion over a period of 60 minutes.|Slow infusion of a dilute solution into a larger vein will minimize patient discomfort and reduce the risk of venous irritation.",
    "validation_result": "Supported",
    "page_location": "Page 32, 21, 12",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "clarithromycin. Phlebitis. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "35",
    "reference": "",
    "matched_paper": "None",
    "matched_evidence": "No matching reference PDF was found for the extraction: 35",
    "validation_result": "Reference Missing",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Reference Filter",
    "analysis_summary": "Validation skipped: Reference Missing",
    "confidence_band": "LOW"
  },
  {
    "statement": "clindamycin. 5.5-7.0. Thrombo-phlebitis. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,36",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 36..Clindamycin Injection_ Package Insert _ Prescribing Info.pdf: Thrombophlebitis has been reported after intravenous infusion.|Avoid prolonged use of indwelling intravenous catheters.",
    "validation_result": "Supported",
    "page_location": "Page 13, Local Reactions",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "daptomycin. 6.8. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,37,38",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 37.Daptomycin Injection_ Package Insert _ Prescribing Info.pdf: Because only limited data are available on the compatibility of daptomycin for injection with other IV substances, additives and other medications should not be added to daptomycin for injection single-dose vials or infusion bags, or infused simultaneously with daptomycin for injection through the same IV line.\n- 38.Cubicin RF (Daptomycin Injection)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: The pH of the solution upon reconstitution is 6.8.",
    "validation_result": "Supported",
    "page_location": "Page 10, Incompatibilities section | Page 4, Description for Cubicin RF",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "dalbavancin. Phlebitis. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,39,40",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 39.Dalbavancin Side Effects_ Common, Severe, Long Term.pdf: Uncommon (0.1% to 1%): Flushing, phlebitis",
    "validation_result": "Supported",
    "page_location": "Page 4, under Cardiovascular",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "delafloxacin meglumine. NR*. Phlebitis. Potential for damage from\nextravasation. Thrombosis of vessel. Local site pain\non Infusion. Redness at\ninjection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,41",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 41.Delafloxacin-Baxdela_ Package Insert _ Prescribing Information.pdf: General disorders and administration site conditions: infusion related reactions",
    "validation_result": "Supported",
    "page_location": "Page 14, Adverse Reactions Occurring in Less Than 2% of Patients Receiving BAXDELA in the ABSSSI (Trials 1 and 2) and CABP (Trial 3) Clinical Trials",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "doripenem. 4.5-5.5. Phlebitis. Thrombo-phlebitis. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "42,43",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 42.Doripenem_ Package Insert _ Prescribing Information.pdf: Doripenem for Injection (doripenem monohydrate) vials contain 500 mg of doripenem on an anhydrous basis, a white to slightly-yellowish off-white sterile crystalline powder. |All references to doripenem activity are expressed in terms of the active doripenem moiety. |The powder is constituted for intravenous infusion. |The pH of the infusion solution is between 4.5 and 5.5.|Most common adverse reactions (≥ 5%) are headache, nausea, diarrhea, rash and phlebitis.",
    "validation_result": "Supported",
    "page_location": "Page 13, Page 2",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "doxycycline hyclate. 1.8-3.3. Thrombo-phlebitis. Potential for damage from\nextravasation. Absolute\nvein patency\nneeded.",
    "reference_no": "1,44",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 44.Doxycycline Injection_ Package Insert _ Prescribing Info.pdf: Each 100 mg vial contains: Doxycycline hyclate, USP equivalent to 100 mg doxycycline; ascorbic\nacid 480 mg; mannitol 300 mg. | pH of the reconstituted solution (10 mg/mL) is between 1.8 and 3.3.|If intravenous therapy is given\nover prolonged periods of time, thrombophlebitis may result.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 10",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "eravacycline. 5.5-7.0. Phlebitis. Thrombo-phlebitis. Local site pain\non Infusion. Redness at\ninjection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,45,46",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 45.Eravacycline Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Hypotension, thrombophlebitis (includes thrombophlebitis, infusion site thrombosis), phlebitis (includes phlebitis, infusion site phlebitis, superficial phlebitis, injection site phlebitis)|Common (1% to 10%): Infusion site reactions (includes catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, superficial phlebitis, thrombophlebitis, vessel puncture site swelling, injection site pain/discomfort, injection site swelling/inflammation), infusion site phlebitis\n- 46.eravacycline - Xerava_ Package Insert _ Prescribing Information.pdf: Each 50 mg single-dose vial contains 50 mg of eravacycline (equivalent to 63.5 mg of eravacycline dihydrochloride) and the excipient, mannitol (150 mg). Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment to 5.5 to 7.0.|Each 100 mg single-dose vial contains 100 mg of eravacycline (equivalent to 127 mg of eravacycline dihydrochloride) and the excipient, mannitol (150 mg). Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment to 5.5 to 7.0.|Infusion site reactions include: catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling.",
    "validation_result": "Supported",
    "page_location": "Page 4, Cardiovascular section | Page 5, Local section | Page 12, Page 8",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ertapenem. 7.5. Phlebitis. Thrombo-phlebitis. Local site pain\non Infusion. Redness at\ninjection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,47",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 47.Ertapenem Monograph for Professionals - Drugs.com.pdf: Gl effects (diarrhea, nausea, vomiting); local reactions (infused vein complication, phlebitis/thrombophlebitis); headache; vaginitis.",
    "validation_result": "Supported",
    "page_location": "Page 7, under Common Adverse Effects",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "erythromicin lactobionate. 6.5-7.7. Local site pain\non Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,48",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 48.Erythrocin Injection_ Package Insert _ Prescribing Info.pdf: The pH of the reconstituted solution is 6.5 - 7.5.|Side effects following the use of intravenous erythromycin are rare. Occasional venous irritation has been encountered, but if the infusion is given slowly, in dilute solution, preferably by continuous intravenous infusion or intermittent infusion in no less than 20 to 60 minutes, pain and vessel trauma are minimized.|Erythrocin Lactobionate-IV (erythromycin lactobionate for injection, USP) must be administered by continuous or intermittent intravenous infusion only.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 11, Page 11",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "fosfomycin 49. Phlebitis.",
    "reference_no": "49",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 49.Fosfomycin Monograph.pdf: Table 6: Adverse Drug Reactions reported by System Organ Class | System Organ Class: General disorders and administration site conditions | Common: Injection site phlebitis",
    "validation_result": "Supported",
    "page_location": "Page 13, Table 6",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "flucloxacillin 50,51. Phlebitis.",
    "reference_no": "50,51",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 51.Flucloxacillin 1.pdf: General disorders and administration site conditions: Phlebitis has followed intravenous infusion.",
    "validation_result": "Supported",
    "page_location": "Page 4, section 4.8 Undesirable effects",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "gentamicin sulfate 1,52. 3.0-5.5. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,52",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 52.Gentamicin Sulfate Injection Concentrate_ Package Insert _ Prescribing Info.pdf: The pH is 4.5 (3.0 to 5.5).|Gentamicin Sulfate Injection, USP is administered by intravenous infusion only after dilution in a 50 or 100 mL ADD-Vantage Flexible Diluent Container of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (See INSTRUCTIONS FOR USE).|Gentamicin sulfate should not be physically premixed with other drugs, but should be administered separately in accordance with the recommended route of administration and dosage schedule.",
    "validation_result": "Supported",
    "page_location": "Page 3, 12, 14",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "imipenem-cilastatin 1,53. 6.5-8.5. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,53",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 53.Imipenem_Cilastatin Monograph for Professionals - Drugs.com.pdf: Adults: Most common adverse effects (>0.2%) include local reactions at the IV infusion site (phlebitis, pain, erythema, vein induration), GI effects (nausea, diarrhea, vomiting), rash, pruritus, urticaria, fever, hypotension, seizures, dizziness, somnolence.",
    "validation_result": "Supported",
    "page_location": "Page 10, Common Adverse Effects",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "meropenem and\nvaborbactam 1,54,55. Phlebitis. Thrombosis of vessel. Local site pain. Redness at injection site.",
    "reference_no": "1,54,55",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 54..Meropenem and vaborbactam Uses, Side Effects & Warnings.pdf: Common side effects of meropenem and vaborbactam may include:\n• swelling or irritation where the medicine was injected.\n- 55.Meropenem and Vaborbactam (Vabomere) Full Prescribing Information. U.S. FDA.pdf: The most frequently reported adverse reactions (3% or greater) in patients receiving\nVABOMERE in the Phase 3 cUTI trial were headache, phlebitis/infusion site reactions, and\ndiarrhea.|Infusion site reactions include infusion/injection site phlebitis, infusion site thrombosis, and infusion site erythema.|General disorders and administration site conditions: pain",
    "validation_result": "Supported",
    "page_location": "Page 1, under the heading \"Meropenem and vaborbactam side effects\" | Page 1, 7, 8, 9",
    "confidence_score": 0.875,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "netilmicin 55,57. 3.5-6.0. Local site pain.",
    "reference_no": "55,57",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 55.Meropenem and Vaborbactam (Vabomere) Full Prescribing Information. U.S. FDA.pdf: The most frequently reported adverse reactions (3% or greater) in patients treated with VABOMERE in the Phase 3 cUTI trial were headache, phlebitis/infusion site reactions, and diarrhea.|Table 3 provides adverse reactions occurring in 1% or greater of patients receiving VABOMERE in the Phase 3 cUTI trial.|Infusion site reactions include infusion/injection site phlebitis, infusion site thrombosis, and infusion site erythema.|General disorders and administration site conditions: pain\n- 57.Netromax Injection (netilmicin sulfate) Package Leaflet  Information for the Patient..pdf: Netromax injections contain Netilmicin sulfate, a semi-synthetic, water-solution antibiotic of the aminoglycoside group.|Injection site or local reaction: Pain at the injection site or local reaction may occur.",
    "validation_result": "Supported",
    "page_location": "Page 7, 8, 9 | Page 1, Page 5",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ofloxacin 58,59,60. 2-9. Phlebitis. Thrombosis of vessel. Local site pain. Redness at injection site.",
    "reference_no": "58,59,60",
    "reference": "",
    "matched_paper": "Multiple PDFs (3/3 support)",
    "matched_evidence": "- 60.Qinolon (ofloxacin hydrochloride) 200 mg per 100 mL Solution for Infusion Product Information..pdf: Local site pain.|Redness at injection site.|Phlebitis.\n- 58.Floxin IV Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Injection site reactions (including phlebitis, swelling, erythema, pain)[Ref]\n- 59.Ofloxacin (Novo-Ofloxacin) Product Monograph. Health Canada. Product Monograph..pdf: Acute Toxicity:\nMice\nM-10\nP.O.\n240, 300, 375, 470, 585, 730\n376",
    "validation_result": "Supported",
    "page_location": "Warnings and Precautions section | Page 10, under the 'Local' section, which refers to IV formulation. | Page 37, Toxicology section, Acute Toxicity",
    "confidence_score": 0.9333333333333332,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 3 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "plazomicin 61,62. 6.5. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "61,62",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 62.ZEMDRI (plazomicin) Injection Full Prescribing Information. U.S. Food and Drug Administration..pdf: Compatibility of ZEMDRI for administration with other drugs has not been established.|ZEMDRI should not be mixed with other drugs or physically added to solutions containing other drugs.|Other medications should not be infused simultaneously with ZEMDRI through the same IV line.",
    "validation_result": "Supported",
    "page_location": "Page 6, Section 2.7 Drug Compatibility",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "lefamulin 1,63. 4.5-5.5. Phlebitis. Local site pain.",
    "reference_no": "1,63",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 63.XENLETA (lefamulin) Injection and Tablets Highlights of Prescribing Information..pdf: Table 2: Adverse Reactions Occurring in ≥2% of Patients Receiving XENLETA in Trial 1\nAdministration site reactions*\n7%\n*Administration site reactions include infusion site pain, infusion site phlebitis, and injection site reaction.",
    "validation_result": "Supported",
    "page_location": "Page 7, Table 2",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "levofloxacin 1,64,65. 3.8-5.8. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Thrombosis of vessel. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,64,65",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 64.Levofloxacin Monograph for Professionals - Drugs.com.pdf: Administer orally or by slow IV infusion. | Do not admix with other drugs or infuse simultaneously through same tubing with other drugs. | Immediately discontinue levofloxacin at first signs or symptoms of any serious adverse reactions.\n- 65.Levofloxacin Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Phlebitis|Common (1% to 10%): Injection site reactions (pain, reddening)",
    "validation_result": "Supported",
    "page_location": "Page 7, Administration | Page 8, IV Infusion | Page 16, Warnings | Page 11, Cardiovascular section | Page 12, Local section",
    "confidence_score": 0.8500000000000001,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "lincomycin\nhydrochloride 1,66. 3.0-5.5. Local site pain. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,66",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 66.Lincomycin Side Effects_ Common, Severe, Long Term.pdf: IM: Pain following injection, local irritation, pain induration, sterile abscess formation",
    "validation_result": "Supported",
    "page_location": "Page 6, Local side effects",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "linezolid 1,67. 4.8. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,67",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 67.Linezolid.pdf: Zyvox\nAntibacterial (oxazolidinone)\npH 4.8",
    "validation_result": "Supported",
    "page_location": "Page 1, under the title LINEZOLID",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "meropenem 1,68. 7.3-8.3. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,68",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 68.Meropenem_ Package Insert _ Prescribing Information.pdf: Local adverse reactions that were reported with meropenem for injection were as follows: Inflammation at the injection site (2.4%), injection site reaction (0.9%), phlebitis/thrombophlebitis (0.8%), pain at the injection site (0.4%), and edema at the injection site (0.2%).|The pH of freshly constituted solutions is between 7.3 and 8.3.",
    "validation_result": "Supported",
    "page_location": "Page 9, Adverse Reactions from Studies of Meropenem for Injection in Other Serious Bacterial Infections (not bacterial meningitis)|Page 13, Meropenem Description",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "metronidazole\nhydrochloride 1,69,70. 4.5-7.0. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site. Absolute vein patency needed. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,69,70",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 69.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Metronidazole Injection, USP has an osmolarity of 310 mOsmol/L (calc) and a pH of 5.5 (4.5 to 7.0).|Each container contains 14 mEq of sodium.|GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Injection site reaction, Malaise, Face edema, Edema peripheral, Chest pain, Chills\n- 70.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Metronidazole Injection, USP has an osmolarity of 310 mOsmol/L (calc) and a pH of 5.5 (4.5 to 7.0).|Each container contains 14 mEq of sodium.|GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Injection site reaction, Malaise, Face edema, Edema peripheral, Chest pain, Chills",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 15 | Page 2, Page 14, Page 15",
    "confidence_score": 0.825,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "minocycline\nhydrochloride 1,71. 4.5-5.0. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,71",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 71.Minocin Injection_ Package Insert _ Prescribing Information.pdf: Each vial contains minocycline hydrochloride (equivalent to 100 mg minocycline), magnesium sulfate heptahydrate and sodium hydroxide (to adjust pH 4.5-5.0).|When diluted in compatible solutions, the pH usually ranges from 4.5 to 6.0.|If intravenous therapy is given over prolonged periods of time, thrombophlebitis may result.|Local Reactions: Injection site erythema and injection site pain.|Additives or other medications should not be added to MINOCIN single-dose vials or infused simultaneously through the same intravenous line including Y-connectors.",
    "validation_result": "Supported",
    "page_location": "Page 14, Page 12, Page 10, Page 13",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "moxifloxacin hydrochloride 1,72. 4.1-4.6. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,72",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 72.Avelox I.V. Side Effects_ Common, Severe, Long Term.pdf: Uncommon (0.1% to 1%): Infusion site extravasation, infusion site thrombophlebitis/phlebitis",
    "validation_result": "Supported",
    "page_location": "Page 12, under the 'Local' section",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "nafcillin sodium 1,73. 6-8.5. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site.",
    "reference_no": "1,73",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 73.Nafcillin Injection (Nafcillin Sodium) RX.pdf: Nafcillin Injection, USP supplied as a premixed frozen solution is to be administered as an intravenous infusion.|Administer slowly over at least 30 to 60 minutes to minimize the risk of vein irritation and extravasation.|With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.|Pain, swelling, inammation, phlebitis, thrombophlebitis, and occasional skin sloughing at the injection site have occurred with intravenous administration of nafcillin (see DOSAGE AND ADMINISTRATION).|Severe tissue necrosis with sloughing secondary to subcutaneous extravasation of nafcillin has been reported.",
    "validation_result": "Supported",
    "page_location": "Page 3, Page 5",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "fosfomycin 49. Additional Consideration. IVOZFO™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not\nrecommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS). IVOZFO™™™\n(fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60\nminutes for an 8 gram dose. Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with\nhigh risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered. Fosfomycin solutions should not be mixed together with other\nparenteral preparations. 49",
    "reference_no": "49",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 49.Fosfomycin Monograph.pdf: IVOZFO™™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not recommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS).|IVOZFO™™ (fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60 minutes for an 8 gram dose.|Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with high risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered.|Although no chemical/pharmaceutical incompatibilities have been found, fosfomycin solutions should not be mixed together with other parenteral preparations.",
    "validation_result": "Supported",
    "page_location": "Page 6 and 8",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "flucloxacillin 50,51. Additional Consideration. It is advisable not to combine flucloxacillin with other drugs in solution for parenteral administration. 50",
    "reference_no": "50,51",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 50.Flucloxacillin.pdf: It is advisable not to combine flucloxacillin with other drugs in solution for parenteral administration.\n- 51.Flucloxacillin 1.pdf: Flucloxacillin may be administered in combination with other antibiotics including ampicillin to produce a wider spectrum of antibacterial activity. | If used concurrently with an aminoglycoside the two antibiotics should not be mixed in the syringe, container or giving set as precipitation may occur. | Flucloxacillin should not be mixed with blood products or other proteinaceous fluids (e.g. protein hydrolysates) or with intravenous lipid emulsions.",
    "validation_result": "Supported",
    "page_location": "Section 6.2 Incompatibilities, page 6 | Section 6.2 Incompatibilities, page 5",
    "confidence_score": 0.975,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "gentamicin sulfate 1,52. Additional Consideration. Do not physically premix with other drugs. Inactivated in solution with beta-lactam antibiotics and vancomycin. Appropriate spacing required because of incompatibilities.¹",
    "reference_no": "1,52",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 52.Gentamicin Sulfate Injection Concentrate_ Package Insert _ Prescribing Info.pdf: Gentamicin sulfate should not be physically premixed with other drugs, but should be administered separately in accordance with the recommended route of administration and dosage schedule.",
    "validation_result": "Supported",
    "page_location": "Page 14, under the section \"For Intravenous Administration\"",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "imipenem-cilastatin 1,53. Additional Consideration. Do not mix with or physically add other antibiotics. May be given through y-tube or three-way stopcock of infusion set. Use small needles and large veins, and rotate infusion sites.¹",
    "reference_no": "1,53",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 53.Imipenem_Cilastatin Monograph for Professionals - Drugs.com.pdf: Do not admix with other antibacterials.",
    "validation_result": "Supported",
    "page_location": "Page 4, under Reconstitution and Dilution",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "meropenem and\nvaborbactam 1,54,55. Additional Consideration. Only compatible with NS. A single dose as an infusion equally distributed over 3 hours.¹",
    "reference_no": "1,54,55",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 54..Meropenem and vaborbactam Uses, Side Effects & Warnings.pdf: Meropenem and vaborbactam is usually given every 8 to 12 hours for up to 14 days. This medicine must be given slowly, and the infusion can take about 3 hours to complete.\n- 55.Meropenem and Vaborbactam (Vabomere) Full Prescribing Information. U.S. FDA.pdf: Administer VABOMERE 4 grams (meropenem 2 grams and\nvaborbactam 2 grams) every 8 hours by intravenous infusion over 3 hours|VABOMERE solution for administration by 3-hour infusion is only compatible with 0.9%\nSodium Chloride Injection, USP.",
    "validation_result": "Supported",
    "page_location": "Page 3, under \"Meropenem and vaborbactam Uses, Side Effects & Warnings\" | Page 1, Dosage and Administration | Page 4, Drug Compatibility",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "netilmicin 55,57. Additional Consideration. Ofloxacin solution for infusion should be administered only by slow IV infusion over a period of 30-60 minutes. Fluoroquinolones, including ofloxacin, are associated with an\nincreased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in\npatients with kidney, heart or lung transplants. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients\nwith known history of myasthenia gravis. 60",
    "reference_no": "55,57",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 57.Netromax Injection (netilmicin sulfate) Package Leaflet  Information for the Patient..pdf: Netromax injections contain Netilmicin sulfate, a semi-synthetic, water-solution antibiotic of the aminoglycoside group.",
    "validation_result": "Supported",
    "page_location": "Page 1, section 1",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ofloxacin 58,59,60. Additional Consideration. Administer ZEMDRI 15 mg/kg every 24 hours by intravenous (IV) infusion over 30 minutes to patients 18 years of age or older with creatinine clearance greater than or equal to 90\nmL/min. ZEMDRI should not be mixed with other drugs or physically added to solutions containing other drugs. Other medications should not be infused simultaneously with\nZEMDRI through the same IV line.62",
    "reference_no": "58,59,60",
    "reference": "",
    "matched_paper": "Multiple PDFs (3/3 support)",
    "matched_evidence": "- 60.Qinolon (ofloxacin hydrochloride) 200 mg per 100 mL Solution for Infusion Product Information..pdf: I am sorry, but I could not find any information about ZEMDRI in the provided document.\n- 58.Floxin IV Side Effects_ Common, Severe, Long Term.pdf: I am sorry, but I could not find any information about ZEMDRI in the document.\n- 59.Ofloxacin (Novo-Ofloxacin) Product Monograph. Health Canada. Product Monograph..pdf: I am sorry, but I could not find any information about ZEMDRI in this document.",
    "validation_result": "Not Found",
    "page_location": "N/A | N/A | Throughout the document",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 3 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "plazomicin 61,62. Additional Consideration. A single dose as an infusion equally distributed over 60 minutes. Do not exceed the recommended rate of administration; may increase the magnitude of QT prolongation. Do not\nadd other additives to the diluent bag because their compatibilities with lefamulin have not been established.¹",
    "reference_no": "61,62",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 61.Plazomicin Uses, Side Effects & Warnings.pdf: Plazomicin is given as an infusion into a vein, every 24 to 48 hours.",
    "validation_result": "Supported",
    "page_location": "Page 2, How is plazomicin given?",
    "confidence_score": 0.75,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "lefamulin 1,63. Additional Consideration. Temporarily discontinue other solutions infusing at the same site and flush tubing with compatible solutions before and after levofloxacin.¹",
    "reference_no": "1,63",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 63.XENLETA (lefamulin) Injection and Tablets Highlights of Prescribing Information..pdf: I am sorry, but I could not find any information about \"lefamulin 1,63. Additional Consideration. Temporarily discontinue other solutions infusing at the same site and flush tubing with compatible solutions before and after levofloxacin.¹\" in the document.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "levofloxacin 1,64,65. Additional Consideration. Manufacturer lists as incompatible with kanamycin and novobiocin. Manufacturer lists the following compatibilities. Infuse properly diluted solution at a rate not to exceed 100\nmL/hr (1 Gm/hr).¹",
    "reference_no": "1,64,65",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 65.Levofloxacin Side Effects_ Common, Severe, Long Term.pdf: Applies to levofloxacin: oral solution, oral tablet.|Other dosage forms:\n• intravenous solution",
    "validation_result": "Supported",
    "page_location": "Page 1, under the title \"Levofloxacin Side Effects\"",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "lincomycin\nhydrochloride 1,66. Additional Consideration. Manufacturer lists as incompatible at the Y-site with amphotericin B (conventional), ceftriaxone (Rocephin), chlorpromazine (Thorazine), diazepam (Valium), erythromycin\n(Erythrocin), pentamidine, phenytoin (Dilantin), and sulfamethoxazole/trimethoprim.¹",
    "reference_no": "1,66",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 66.Lincomycin Side Effects_ Common, Severe, Long Term.pdf: I am sorry, but I could not find any information about the incompatibility of lincomycin hydrochloride with amphotericin B, ceftriaxone, chlorpromazine, diazepam, erythromycin, pentamidine, phenytoin, and sulfamethoxazole/trimethoprim in the provided document.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "linezolid 1,67. Additional Consideration. Meropenem should not be mixed or physically added to solutions containing other drugs; compatibility not established.¹",
    "reference_no": "1,67",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 67.Linezolid.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "Entire document",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "meropenem 1,68. Additional Consideration. Administer separately, discontinue the primary IV during administration and do not introduce additives into the solution.¹ Local reactions include thrombophlebitis after intravenous\ninfusion. This reaction can be minimized or avoided by avoiding prolonged use of indwelling intravenous catheters. 69 Administer by slow intravenous drip infusion only, either as a\ncontinuous or intermittent infusion. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion.70",
    "reference_no": "1,68",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 68.Meropenem_ Package Insert _ Prescribing Information.pdf: Meropenem for Injection, USP is supplied in a single-dose vial containing meropenem as awhite to slight yellow crystalline powder powder to deliver 2 grams of meropenem for intravenous administration after reconstitution.|The dry powder should be stored at 20°C to 25°C (68°F to 77°F).|Brief exposure to 15°C to 30°C (59°F to 86°F) is permitted [see USP Controlled Room Temperature].|Local adverse reactions that were reported with meropenem for injection were as follows: Inflammation at the injection site (2.4%), injection site reaction (0.9%), phlebitis/thrombophlebitis (0.8%), pain at the injection site (0.4%), and edema at the injection site (0.2%).",
    "validation_result": "Supported",
    "page_location": "Pages 9, 21",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "metronidazole\nhydrochloride 1,69,70. Additional Consideration. Additives or other medications should not be added to the minocycline vial or infused simultaneously through the same IV line, including Y-connectors. If the same IV line is used for\nsequential infusion of additional medications, the line should be flushed before and after infusion of minocycline with NS, dextrose, dextrose in saline solutions, or LR.¹",
    "reference_no": "1,69,70",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 69.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. Additives should not be introduced into Metronidazole Injection, unless compatibility is known.\n- 70.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. Additives should not be introduced into Metronidazole Injection, unless compatibility is known.",
    "validation_result": "Supported",
    "page_location": "Page 17, Important Administration and Preparation Instructions | Page 17, Important Administration and Preparation Instructions",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "minocycline\nhydrochloride 1,71. Additional Consideration. Manufacturer states, \"Other IV substances, additives, or other medications should not be added to moxifloxacin or infused simultaneously through the same IV line.\" Flush line with a\nsolution compatible to both drugs before and after administration of moxifloxacin and/or any other drug through the same IV line. May be administered through a Y-tube.¹",
    "reference_no": "1,71",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 71.Minocin Injection_ Package Insert _ Prescribing Information.pdf: Additives or other medications should not be added to MINOCIN single-dose vials or infused simultaneously through the same intravenous line including Y-connectors. |If the same intravenous line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of MINOCIN with Sodium Chloride Injection USP, Dextrose Injection USP, Dextrose and Sodium Chloride Injection USP, or Lactated Ringer's Injection USP.",
    "validation_result": "Supported",
    "page_location": "Page 13, Incompatibilities section",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "moxifloxacin\nhydrochloride 1,72. Additional Consideration. Inactivated in solution with aminoglycosides (e.g., amikacin, gentamicin). Do not mix in the same solution. Appropriate spacing and/or separate sites required. May be infused over\n5 to 10 minutes.¹",
    "reference_no": "1,72",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 72.Avelox I.V. Side Effects_ Common, Severe, Long Term.pdf: No relevant information found in the document.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "nafcillin sodium 1,73. Additional Consideration. IVOZFO™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not\nrecommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS). IVOZFO™™™\n(fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60\nminutes for an 8 gram dose. Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with\nhigh risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered. Fosfomycin solutions should not be mixed together with other\nparenteral preparations. 49",
    "reference_no": "1,73",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 73.Nafcillin Injection (Nafcillin Sodium) RX.pdf: I am sorry, but I could not find any information about IVOZFO™ (fosfomycin for injection) in this document. The document is about Nafcillin Injection (Nafcillin Sodium).",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "omadacycline. Phlebitis. Potential for damage from extravasation. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,74",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 74.Nuzyra Package Insert  Prescribing Information.pdf: †Infusion site extravasation, pain, erythema, swelling, inflammation, irritation, peripheral swelling and skin induration.",
    "validation_result": "Supported",
    "page_location": "Page 11, Table 5: Adverse Reactions Occurring in ≥2% of Patients Receiving NUZYRA in Pooled Trials 2 and 3",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "oritavancin. 3.1-4.3. Phlebitis. Potential for damage from extravasation. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,75",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 75.Orbactiv Package Insert Prescribing Info.pdf: The following selected adverse reactions were reported in ORBACTIV-treated patients at a rate of less than 1.5%:\nGeneral disorders and administration site conditions: infusion site erythema, extravasation,|In the pooled ABSSSI clinical trials, the most common reported reactions leading to discontinuation were cellulitis (4/976, 0.4%) and osteomyelitis (3/976, 0.3%).|Infusion Related Reactions: Administer ORBACTIV over 3 hours to minimize infusion.",
    "validation_result": "Supported",
    "page_location": "Page 9, Page 8, Page 2",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "oxacillin. 6-8.5. Phlebitis. Thrombo-phlebitis. Local site pain on Infusion. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,76,77",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 76.Oxacillin  Davis's Drug Guide for Rehabilitation Professionals.pdf: Local: pain at IM site, phlebitis at IV site.",
    "validation_result": "Supported",
    "page_location": "Page 2, Adverse Reactions/Side Effects",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "penicillin g aqueous. 5.5-8. Phlebitis. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,78",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 78.Oxacillin Injection Package Insert Prescribing Info.pdf: The pH is 6.5 (6.0 to 8.5).|With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 8",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "piperacillin-tazobactam. 5.5-6.8. Phlebitis. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,79,80",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 79.Penicillin G Injection  Package Insert  Prescribing Info.pdf: Phlebitis and thrombophlebitis may occur, and pain at the injection site has been reported with intravenous administration.\n- 80.Piperacillin and Tazobactam Package Insert Prescribing Info.pdf: Phlebitis (1.3%)",
    "validation_result": "Supported",
    "page_location": "Page 11, Local Reactions | Page 15, Adverse Reactions/Side Effects",
    "confidence_score": 0.875,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "rifampim. 7.8-8.8. Phlebitis. Potential for damage from extravasation. Redness at injection site. Absolute vein patency needed. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,81",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 81.Piperacillin and tazobactam Uses, Side Effects & Warnings.pdf: Piperacillin and tazobactam is given as an infusion into a vein.",
    "validation_result": "Supported",
    "page_location": "Page 3, under the section \"How should I use piperacillin and tazobactam?\"",
    "confidence_score": 0.6,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "sulfamethoxazole-trimethoprim. 9.5-10.5. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,82",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 82.Rifampin Injection Package Insert Prescribing Information.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "tedizolid. 7.4-8.1. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,83",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 83.Sulfamethoxazole and TrimethoprimPackage Insert  Prescribing Info.pdf: None",
    "validation_result": "Not Found",
    "page_location": "",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "teicoplanin. 7.2-7.8. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "84,85",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 84.SIVEXTRO (tedizolid phosphate) Highlights of Prescribing Information..pdf: The most common adverse reactions (>2%) in pediatric patients (12 years to less than 18 years of age) are phlebitis and increased hepatic transaminases. (6.1)|The most common adverse reactions (>2%) in pediatric patients (less than 12 years of age) are infusion- or injection-related adverse reactions and vomiting. (6.1)|*Includes adverse reactions in the following body system or organ classes: General disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, and vascular disorders, including but not limited to, phlebitis, injection- or infusion-site pain, injection- or infusion-site swelling, injection-site erythema, injection-site induration, and infusion-related reaction.\n- 85.Teicoplanin  Injection Infusion or Oral Solution Package Leaflet..pdf: The final solution is isotonic with plasma and has a pH of 7.2-7.8.|problems where the injection was given - such as reddening of the skin, pain or swelling",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 7 | Page 7, Page 5",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "televancin. 4.5-5.0. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,86",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 86.Teicoplanin (Targocid) Injection Summary of Product Characteristics..pdf: In addition, infusion-related events, such as erythema or flushing of the upper body, have been rarely reported in which the events occurred without a history of previous teicoplanin exposure and did not recur on reexposure when the infusion rate was slowed and/or the concentration decreased.",
    "validation_result": "Supported",
    "page_location": "Page 3, Adverse Reactions",
    "confidence_score": 0.75,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "ticarcillin & clavulanate. 5.5-7.5. Phlebitis. Thrombo-phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "87,88",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 87.Vibativ Package Insert  Prescribing Information.pdf: VIBATIV is administered intravenously. Because only limited data are available on the compatibility of VIBATIV with other IV substances, additives or other medications should not be added to VIBATIV single-dose vials or infused simultaneously through the same IV line.\n- 88.Clavulanate  Ticarcillin Side Effects Common, Severe, Long Term.pdf: Common (1% to 10%): Injection site phlebitis|Postmarketing reports: Injection site pain, injection site burning, injection site swelling, injection site induration, thrombophlebitis with IV administration",
    "validation_result": "Supported",
    "page_location": "Page 7, Section 2.4 Preparation and Administration | Page 3, Local adverse effects",
    "confidence_score": 0.875,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "tigecycline. 7.8. Phlebitis. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,89,90",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 90.Tigecycline Package Insert  Prescribing Information.pdf: The following adverse reactions were reported (<2%) in patients receiving tigecycline in clinical studies: | Body as a Whole Injection site inflammation, injection site pain, injection site reaction, septic shock, allergic reaction, chills, injection site edema, injection site phlebitis",
    "validation_result": "Supported",
    "page_location": "Page 14, Section 6. Adverse Reactions/Side Effects",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "tobramycin. 3.0-6.5. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,91,92",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 91.Tigecycline Side Effects Common, Severe, Long Term.pdf: Common (1% to 10%): Phlebitis | Frequency not reported: Injection site pain, injection site inflammation, injection site reaction, injection site phlebitis, injection site edema[Ref] | • swelling, tenderness, or pain at the injection site | • red streaks on the skin\n- 92.Tobramycin Package Insert  Prescribing Information.pdf: Each mL contains tobramycin sulfate equivalent to 10 mg (pediatric) or 40 mg tobramycin; sodium metabisulfite added as an antioxidant 3 mg; and edetate disodium added as a stabilizer, 0.1 mg. | Contains sulfuric acid and may contain sodium hydroxide for pH adjustment. pH 4.0 (3.0 to 6.5).|Other reported adverse reactions possibly related to tobramycin include anemia, granulocytopenia, and thrombocytopenia; and fever, rash, exfoliative dermatitis, itching, urticaria, nausea, vomiting, diarrhea, headache, lethargy, pain at the injection site, mental confusion, and disorientation.|Tobramycin Injection, USP should not be physically premixed with other drugs but should be administered separately according to the recommended dose and route.",
    "validation_result": "Supported",
    "page_location": "Page 5, 7, 8 | Page 3, Page 10, Page 16",
    "confidence_score": 0.875,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "vancomycin. 2.5-5.0. Phlebitis. Thrombo-phlebitis. Thrombosis of vessel. Local site pain on Infusion. Absolute vein patency needed. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,93,94,95",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 94.Vancomycin Hydrochloride Package Insert Prescribing Info.pdf: Administer Vancomycin by a secure intravenous route of administration to reduce the risk of local irritation and phlebitis reactions [see Warnings and Precautions (5.8)].|Inflammation at the injection site has been reported. Vancomycin is irritating to tissue and must be given by a secure intravenous route of administration. Thrombophlebitis may occur, the frequency and severity of which can be minimized by slow infusion of the drug and by rotation of venous access sites.|General Disorders and Administration Site Conditions: General discomfort, drug fever, chills, phlebitis, injection site irritation, injection site pain and necrosis following intramuscular injection, chemical peritonitis following intraperitoneal administration (Vancomycin Injection is not approved for intramuscular and intraperitoneal administration)\n- 95.Drouet,2015.pdf: Peripheral intravenous therapy is frequently used in routine hospital practice and, due to various factors, its most common side effect is phlebitis.|The infusion of vancomycin is particularly associated with phlebitis despite its widespread use.|ntravenous (i.v.) therapy is one of the most common routine medical practices performed in hospitals, due to the increasing complexity of disease processes. Numerous complications, including phlebitis, thrombophlebitis, extravasations and infections are however associated with peripheral i.v. (p.i.v.) therapy.|Phlebitis is the most common side effect and may occur at rates ranging from 30 to 70% (1-4), depending on various factors.|Infusion phlebitis is an inflammation of the vein endothelium without infection and is characterized by pain, redness, swelling, and warmth at the i.v. site.|Phlebitis is a real public health problem, due to the risk of thrombophlebitis, which increases pain and prolongs hospital stays.",
    "validation_result": "Supported",
    "page_location": "Page 5, 11, 12 | Page 1, Introduction",
    "confidence_score": 0.875,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "omadacycline 1,74. Additional Consideration. Manufacturer states, \"Do NOT administer omadacycline with any solution containing multivalent cations (e.g., calcium and magnesium) through the same intravenous line. The\ncompatibility of omadacycline with other drugs and infusion solutions other than D5W or NS has not been established.¹",
    "reference_no": "1,74",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 74.Nuzyra Package Insert  Prescribing Information.pdf: NUZYRA for Injection: Do NOT administer NUZYRA for injection with any solution containing multivalent cations, e.g., calcium and magnesium, through the same intravenous line [see Drug Interactions (7.2)] . The compatibility of NUZYRA with other drugs and infusion solutions other than 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP has not been established.",
    "validation_result": "Supported",
    "page_location": "Page 4, Section 2.1 Important Administration Instructions and Page 7, Section 2. The compatibility of NUZYRA with other drugs and infusion solutions other than 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP has not been established.",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "oritavancin 1,75. Additional Consideration. Use only D5W for dilution. Do NOT use NS. NS is incompatible with oritavancin and may cause precipitation of the drug. Other IV substances, additives, or other medications mixed\nin NS should not be added to oritavancin single-use vials or infused simultaneously through the same IV line or through a common IV port. In addition, drugs formulated at a basic\nor neutral pH may be incompatible with oritavancin. If the same IV line is used for sequential infusion of additional medications, the line should be flushed before and after infusion\nof oritavancin with D5W.¹",
    "reference_no": "1,75",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 75.Orbactiv Package Insert Prescribing Info.pdf: Dilution: Use ONLY 5% dextrose injection (D5W) for dilution to prepare the final intravenous solution for infusion. |Do NOT use Sodium Chloride Injection for dilution as it is incompatible with ORBACTIV and may cause precipitation of the drug. |Therefore other intravenous substances, additives or other medications mixed in sodium chloride injection should not be added to ORBACTIV single-dose vials or infused simultaneously through the same IV line or through a common intravenous port. |In addition, drugs formulated at a basic or neutral pH may be incompatible with ORBACTIV. |If the same intravenous line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of ORBACTIV with D5W.",
    "validation_result": "Supported",
    "page_location": "Page 4, Section 2.3 and Page 5, Section 2.5",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "oxacillin 1,76,77. Additional Consideration. Do not physically mix with other agents.\" May degrade in infusion solutions containing acidic agents. Inactivated in solution with aminoglycosides (e.g., amikacin, gentamicin). Do\nnot mix in the same solution. Appropriate spacing and/or separate sites required. May be administered in specific IV solutions (check literature) over up to a 6-hour period. In\ninjection 1 Gm (10 mL) or fraction thereof slowly over 10 minutes.¹",
    "reference_no": "1,76,77",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 76.Oxacillin  Davis's Drug Guide for Rehabilitation Professionals.pdf: I am sorry, but I could not find any information about oxacillin mixing with other agents, degradation in acidic solutions, inactivation with aminoglycosides, or administration times in the provided document.",
    "validation_result": "Not Found",
    "page_location": "Entire document",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "penicillin g aqueous 1,78. Additional Consideration. Do not mix in the same solution. Appropriate spacing and/or separate sites required. Do not mix in the same solution. Appropriate spacing and/or separate sites required. Administer\nas ordered as continuous IV drip; for example, 5 million units in 1,000 mL of D5W over 12 hour.¹",
    "reference_no": "1,78",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 78.Oxacillin Injection Package Insert Prescribing Info.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.2,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "piperacillin-tazobactam 1,79,80. Additional Consideration. Should not be mixed with other drugs in a syringe or infusion bottle. Manufacturer recommends temporarily discontinuing other solutions infusing at the same site to avoid\ncompatibility problems. Piperacillin may inactivate aminoglycosides (e.g., amikacin, gentamicin). Do not mix in the same solution. Separate administration required. Formulation\ncontaining EDTA may be compatible at the Y-site with amikacin or gentamicin. A single dose over 30 minutes as an intermittent infusion. Discontinue primary IV infusion during\nadministration. Current data show that giving IV push over 2 to 3 minutes has been generally safe and tolerable when reconstituted with SWI 20 mL.¹",
    "reference_no": "1,79,80",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 80.Piperacillin and Tazobactam Package Insert Prescribing Info.pdf: Piperacillin and tazobactam for injection should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.|Due to the in vitro inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam and aminoglycosides are recommended for separate administration.|Piperacillin and tazobactam for injection and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated [seeDrug Interactions (7.1)].|Administer by infusion over a period of at least 30 minutes.|During the infusion it is desirable to discontinue the primary infusion solution.",
    "validation_result": "Supported",
    "page_location": "Page 8, Drug Interactions on page 19, Page 9",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "rifampim 1,81. Additional Consideration. \"May form a precipitate with diltiazem (Cardizem) at the Y-site.\" Infusion solutions other than D5W or NS are not recommended. A single dose diluted in 500 mL equally distributed\nas an infusion over 3 hours. In selected situations a single dose diluted in 100 mL may be administered over 30 minutes.¹",
    "reference_no": "1,81",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 81.Piperacillin and tazobactam Uses, Side Effects & Warnings.pdf: No relevant information found in the document.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "sulfamethoxazole-\ntrimethoprim 1,82. Additional Consideration. Manufacturer states, \"Do not mix with other drugs or solutions.\" infusion. A single dose must be infused over 60 to 90 minutes. Avoid rapid infusion or bolus injection.¹",
    "reference_no": "1,82",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 82.Rifampin Injection Package Insert Prescribing Information.pdf: No direct match found.",
    "validation_result": "Not Found",
    "page_location": "Entire document",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "tedizolid 1,83. Additional Consideration. Other IV substances, additives, or other medications should not be added to tedizolid single-use vials or infused simultaneously through the same IV line or through a common IV\nport. If the same IV line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of tedizolid with NS.\" It is incompatible with any\nsolution containing divalent cations (e.g., calcium, magnesium), including LR injection and Hartmann's solution. Do not administer as an IV push or bolus.¹",
    "reference_no": "1,83",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 83.Sulfamethoxazole and TrimethoprimPackage Insert  Prescribing Info.pdf: The provided document does not mention tedizolid or its incompatibility with divalent cations or specific IV administration guidelines.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "teicoplanin 84,85. Additional Consideration. Solutions of teicoplanin and aminoglycosides are incompatible when mixed directly and should not be mixed before injection.85",
    "reference_no": "84,85",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 85.Teicoplanin  Injection Infusion or Oral Solution Package Leaflet..pdf: In particular, tell your doctor, pharmacist or nurse if you are taking the following medicines:\n• Aminoglycosides as they must not be mixed together with teicoplanin in the same injection.",
    "validation_result": "Supported",
    "page_location": "Page 2, under 'Other medicines and teicoplanin'",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "televancin 1,86. Additional Consideration. Manufacturer states, \"Additives or other medications should not be added to telavancin single-use vials or infused simultaneously through the same IV line. If the same IV line is\nused for sequential infusion of additional medications, the line should be flushed before and after infusions of telavancin with D5W, NS, or LR. A single dose equally distributed as an\ninfusion over 60 minutes.¹",
    "reference_no": "1,86",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 86.Teicoplanin (Targocid) Injection Summary of Product Characteristics..pdf: No relevant information found in the document.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "ticarcillin & clavulanate 87,88. Additional Consideration.",
    "reference_no": "87,88",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 88.Clavulanate  Ticarcillin Side Effects Common, Severe, Long Term.pdf: Link AS, Jr (1985) \"Efficacy and safety of ticarcillin plus clavulanic acid and piperacillin in patients with lower respiratory tract infections.\"|Mostow SR, O'Brien RF (1985) \"Safety and effectiveness of ticarcillin plus clavulanate potassium in treatment of lower respiratory tract infections.\"|Sanders CV, Marier RL, Aldridge KE, Derks FW, Martin DH (1985) \"Safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women.\"|Gentry LO, Macko V, Lind R, Heilman A (1985) \"Ticarcillin plus clavulanic acid (timentin) therapy for osteomyelitis.\"|Tehan S, Horobin J, Gordonsmith R, McLatchie GR (1988) \"Ticarcillin plus clavulanic acid (timentin): further UK trial results.\"",
    "validation_result": "Supported",
    "page_location": "Page 4, References",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "tigecycline 1,89,90. Additional Consideration. The following drugs should not be administered simultaneously through the same Y-site as tigecycline: amphotericin B (conventional), amphotericin B lipid complex, diazepam,\nesomeprazole, and omeprazole .Flush IV line with D5W, NS, or LR before and after infusion of tigecycline if other drugs are administered through the same line.",
    "reference_no": "1,89,90",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 90.Tigecycline Package Insert  Prescribing Information.pdf: The following drugs should not be administered simultaneously through the same Y-site as tigecycline: amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, and omeprazole.|Tigecycline may be administered intravenously through a dedicated line or through a Y-site. |If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of tigecycline with 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP or Lactated Ringer's Injection, USP.",
    "validation_result": "Supported",
    "page_location": "Page 7, Section 2.7 Drug Incompatibilities and Section 2.5 Preparation and Administration",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "tobramycin 1,91,92. Additional Consideration. Manufacturer states, \"Do not physically premix with other drugs; administer separately.\" Inactivated in solution with beta-lactam antibiotics (e.g., cephalosporins, penicillins) and\nvancomycin; do not mix in the same solution. Appropriate spacing required because of physical incompatibilities.¹",
    "reference_no": "1,91,92",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 92.Tobramycin Package Insert  Prescribing Information.pdf: Tobramycin Injection, USP should not be physically premixed with other drugs but should be administered separately according to the recommended dose and route.|The inactivation of tobramycin and other aminoglycosides by ẞ-lactam-type antibiotics (penicillins or cephalosporins) has been demonstrated in vitro and in patients with severe renal impairment.",
    "validation_result": "Supported",
    "page_location": "Page 16, Page 9",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "vancomycin 1,93,94,95. Additional Consideration. Administer continuous vancomycin infusions via a CVAD. In a small study, thrombophlebitis occurred in all patients receiving the infusion via a midline catheter, regardless of\ndilution, as assessed via daily ultrasound (IV). 93 Several sources recommend not admixing with other drugs. They suggest it is incompatible with alkaline solutions (e.g., aminophylline,\naztreonam, barbiturates, chloramphenicol, dexamethasone, sodium bicarbonate) and may form a precipitate with heavy metals. May inactivate aminoglycosides; should also not be\ncombined in the same solution with albumin, selected cephalosporins, foscarnet, or selected penicillins; if administered concurrently, administer at separate sites or separate intervals\n(flush IV line with a compatible solution before and after administration). A single dose properly diluted (concentration of no more than 5 mg/mL) at a rate not to exceed 10 mg/min\nor 60 minutes, whichever is longer. Another reference suggests each 500-mg increment over a minimum of 30 minutes.¹",
    "reference_no": "1,93,94,95",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 94.Vancomycin Hydrochloride Package Insert Prescribing Info.pdf: Vancomycin Injection concentrations of no more than 5 mg/mL are recommended in adults [see Dosage and Administration (2.2)].|Administer Vancomycin Injection over a period of 60 minutes or greater to reduce the risk of rapid-infusion-related adverse reactions.\n- 95.Drouet,2015.pdf: The rate of vancomycin-induced phlebitis through intermittent infusion varies from 0 to 18% for a known concentration of 4 to 5 mg/ml over 1 h (17, 18).|As for continuous infusion, Farber and Moellering, using an infusion of 4 mg/ml over 24 h, reported a phlebitis rate of 13% (19).",
    "validation_result": "Supported",
    "page_location": "Page 5, Dosage and Administration | Page 2, paragraph 2",
    "confidence_score": 0.825,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "Reference.",
    "reference_no": "None",
    "reference": "No citation identified in the source text.",
    "matched_paper": "None",
    "matched_evidence": "The system could not identify a superscript or citation number for this specific statement in the PDF.",
    "validation_result": "Refuted",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "",
    "analysis_summary": "This statement was extracted but has no linked reference number to validate against.",
    "confidence_band": "LOW"
  }
]